Ridaxa

Ridaxa is a localized pharmaceutical brand dedicated to providing specialized antibiotic treatments, specifically containing Rifaximin. It is primarily used for gastrointestinal conditions such as traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy. The brand is a key product within the portfolio of the Egyptian pharmaceutical market, catering to both domestic needs and regional distribution.

Ridaxa is owned and manufactured by Marcyrl Pharmaceutical Industries, a significant Egyptian company established in the late 20th century. Marcyrl has grown into a major player in the Middle East and North Africa (MENA) region, focusing on the development and production of high-quality generic medications that offer affordable therapeutic alternatives. The product is manufactured in their state-of-the-art facilities located in Cairo, Egypt, following international GMP standards.